Goodwin advised Flagship Pioneering on the investment. Evelo Biosciences, Inc. (Nasdaq:EVLO) announced a securities purchase agreement with investors in a private placement to sell 11,025,334 shares of...
You must be a Standard 1 Year member to access this content.
Goodwin advised ReNAgade Therapeutics on the fundraising. ReNAgade Therapeutics announced a $300 million Series A financing round led by MPM BioImpact and F2 Ventures. ReNAgade has...
You must be a Standard 1 Year member to access this content.
Goodwin advised ElevateBio on the financing. ElevateBio, LLC announced the closing of its $401 million Series D financing led by the AyurMaya Capital Management Fund, managed by...
You must be a Standard 1 Year member to access this content.
Gibson, Dunn & Crutcher LLP acted for Dianthus Therapeutics, Inc. on its merger with Magenta Therapeutics, Inc., assisted by Goodwin Procter. Magenta Therapeutics, Inc. (Nasdaq: MGTA) and Dianthus Therapeutics,...
You must be a Standard 1 Year member to access this content.
Goodwin advised Haystack Oncology on the deal. Haystack Oncology announced its definitive agreement to be acquired by Quest Diagnostics (NYSE: DGX). Under the terms of the agreement,...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Avadel Pharmaceutics on the deal. Avadel announced its royalty agreement with RTW Investments, LP and certain of its affiliates for up to $75 million....
You must be a Standard 1 Year member to access this content.
Goodwin advised Avadel on the deal. Avadel extended the maturity of $96.2 million of its convertible notes to 2027. Under the terms of the convertible note exchange...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised Avadel Pharmaceutics plc on the deal. Avadel Pharmaceuticals announced an underwritten public offering of 10,000,001 of its ordinary shares, nominal value $0.01 per...
You must be a Standard 1 Year member to access this content.
Goodwin advised OncoC4 on the deal. OncoC4 announced its agreement with BioNTech SE pursuant to which BioNTech receives an exclusive worldwide license to co-develop and commercialize OncoC4’s...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised BridgeBio Pharma on the offering, and Latham & Watkins advised the underwriters involved. BridgeBio Pharma, Inc. announced the pricing on March 7, 2023 of...
You must be a Standard 1 Year member to access this content.
Goodwin Procter advised TPI Composites, Inc. on the deal. Davis Polk advised the representative of the initial purchasers and the counterparties to the capped call transactions...
You must be a Standard 1 Year member to access this content.
Goodwin advised TCR² Therapeutics Inc. on the deal while Ropes & Gray represented Adaptimmune Therapeutics plc. TCR² Therapeutics Inc. (NASDAQ: TCRR) announced its definitive agreement with Adaptimmune...
You must be a Standard 1 Year member to access this content.
